Welcome to the Newsroom
10 July 2017
Prima BioMed Announces Approval for the Initiation of the ‘INSIGHT’ Clinical Trial
SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima” the “Company”) today announced that its collaboration partner, the Institute of Clinical Cancer Research, Krankenhaus Nordwest GmbH in Frankfurt Germany (“IKF”), has received the regulatory and ethical approvals for the clinical trial investigating IMP321 in new settings, called ”INSIGHT”.
Article as pdf